On September 8, 2026 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), reported that members of its executive leadership team will present at and participate in the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14–16 in New York City. Genprex is a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes. The Company’s lead oncology program is in clinical development, and its diabetes program is advancing through preclinical development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ryan Confer, Genprex’s President and Chief Executive Officer, will provide an overview of Reqorsa Gene Therapy, the Company’s lead clinical oncology candidate, and its preclinical diabetes program. He will also discuss the development priorities for each program.

Mark Berger, MD, Genprex’s Chief Medical Officer, and Thomas Gallagher, Genprex’s Senior Vice President of Intellectual Property and Licensing, will also attend the conference and participate in one-on-one investor meetings.

Company Presentation Details:

Date: Monday, September 14, 2026

Time: 3:30-4 p.m. ET

Location: Lotte New York Palace Hotel, Holmes I (4th Floor), New York, NY

Registered attendees may request one-on-one meetings with Genprex management via H.C. Wainwright.

(Press release, Genprex, SEP 8, 2026, https://www.genprex.com/2026/09/08/genprex-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference/ [SID1234670620])